In non-small cell lung cancer (NSCLC), EHMT2 inhibition leads to cancer cell death via autophagy induction, in which sterol regulatory element-binding protein 2 (SREBF2) expression is a crucial contributor.54 SREBF2 can communicate with the autophagy process by binding to the promoters of several autophagy genes, such as Map1lc3b, ATG4b, and ATG4d.55 Here, EHMT2 inhibition robustly decreases H3K9me1 and H3K9me2 at the promoter of the SREBF2 locus, resulting in upregulated SREBF2 expression and, consequently, autophagy-mediated cell death. The gene discussed is MAP1LC3B; the disease is non-small cell lung carcinoma.